💨 Abstract
Aclaris Therapeutics reported a Q2 loss of $15.4 million, equating to 13 cents per share, which met analysts' expectations. Revenue surpassed forecasts at $1.8 million. The company's shares recently closed at $1.55, up from $1.22 a year ago.
Courtesy: WTOP Staff
Suggested
Wilson and Dart lead Giants to 34-25 preseason win over Bills -
Deandre Kerr scores in second-half stoppage time to rally Toronto to 1-1 draw with Union -
CeeDee Lamb takes big hit from sprinting official while WR is in street clothes on the sideline -
Winning numbers drawn in Saturday’s Maryland Cash Pop -
Mariano Rivera tears his Achilles tendon in Yankees’ Old-Timers’ Day game -
NASCAR-Xfinity Mission 200 At The Glen Results -
¿Qué pasó en el atentado contra Miguel Uribe Turbay, senador colombiano? Lo que se sabe del ataque y los sospechosos -
Los viajes de algunas figuras de Morena ponen en duda el discurso de austeridad del partido -
People with developmental disabilities seeing Medicaid coverage lapse more often in Maryland -
Teens allegedly trash store at Hechinger Mall in Northeast DC -